Our Purpose and Values
A Message from our Executive Sponsors
Fellowship Opportunities
US Medical Affairs
Global Regulatory Affairs, Patient Safety and Quality Assurance (GRAPSQA)
Program History
About the Rutgers Component
Key Program Features
Application Process and Eligibility Requirements
Current Fellows
Executive Leadership
Program Leadership
About AstraZeneca
We push the boundaries of science to deliver life-changing medicines.

Our purpose underpins everything we do. It gives us a reason to come to work every day. It reminds us why we exist as a company. It helps us deliver benefits to patients and create value for shareholders. It also sets the context for our employees’ activities and the roles of our teams, partners and other collaborators.

We follow the science. We put patients first. We play to win. We do the right thing. We are entrepreneurial.

Our values determine how we work together and the behaviors that are integral to our drive for success. Our values guide our decision making, define our beliefs and foster a strong AstraZeneca culture.

“AstraZeneca has completed the first phase in its strategic journey. We have rebuilt strong foundations for sustainable delivery and are on track to return to growth by 2017. Our efforts are creating significant value for patients and shareholders. “

Pascal Soriot
Chief Executive Officer
On behalf of AstraZeneca and the Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey, we would like to thank you for your interest in our fellowship program in US Medical Affairs and US Commercial Oncology. Our partnership with the Rutgers Institute for Pharmaceutical Industry Fellowships allows us to participate in the growth and development of the next generation of industry-based pharmacists.

As a global biopharmaceutical company, AstraZeneca provides innovative medicines for some of the world’s most serious diseases. Pioneering new scientific ideas means never settling for second best and always being ready to challenge the status quo. That’s why we look for people who share our thirst for knowledge, our love of innovation and our ambitious approach to self-improvement. If that’s you, why not discover everything that makes us a destination of choice for some of the brightest people in the global biopharmaceutical industry?

We value the talents and skills of our 61,500 employees in more than 100 countries. Our people strategy, which supports our strategic priority of being a great place to work, is built around four key pillars: build and develop organizations and capabilities; develop a strong and diverse pipeline of leaders; drive a vibrant, high-performing culture; and generate a passion for people development. This means we place emphasis on effective leadership, the acquisition and retention of great talent, setting clear targets, open lines of communications, excellent learning and development opportunities and a healthy, safe and energizing workplace – within a performance culture in which diversity is valued and individual success depends solely on personal merit and performance.

Your fellowship experience at AstraZeneca will yield a broad overview of key functions within the biopharmaceutical industry through real-world experiences and learnings. You will have the opportunity to engage with dedicated professionals who are pushing the boundaries of science to deliver life-changing medicines.

All of us at AstraZeneca, we wish you much success and hope you strongly consider the AstraZeneca Fellowship Program as an investment in your personal career development and growth.
The US Medical Affairs team is comprised of individuals dedicated to our mission: *Using our deep therapeutic knowledge, we generate and translate science in order to advance healthcare outcomes for patients.*

With purpose, common values and ambition, our team delivers on our priorities to deliver life-changing medicines.

### Global Regulatory Affairs, Patient Safety and Quality Assurance (GRAPSQA)

**Global Regulatory Affairs - Gaithersburg, MD (1)**

**Global Patient Safety - Gaithersburg, MD (1)**

The AstraZeneca GRAPSQA Fellowship Program is a focused two-year program that provides both US and Global experience. The fellows will establish drug development and regulatory/safety foundational knowledge and gain experience working on both development and life-cycle products. In addition, the fellowship will provide training on developing regulatory strategy for approval and maintenance of drugs and biologics.

**US Medical Affairs, Oncology Business Unit**

**Medical Strategy - Immuno-Oncology - Gaithersburg, MD (1)**

**Health Economics & Outcomes Research (HEOR) / Managed Markets (MM) - Gaithersburg, MD (1)**

During the introductory months of the program, our fellows gain broad exposure to the inner workings of a medical affairs department. The functional areas include medical information, publication strategy & planning, patient safety, managed care, medical policy & quality, research and evidence generation (including Risk Evaluation and Mitigation Strategy), learning & development, medical education & grants, compliance/adherence and project management/executive operations.

The remainder of the fellowship, the fellow will have an in-depth experience in Immuno-Oncology or Health Economics & Outcomes Research/Managed Markets whereby the fellow will be an integral member and contributor of their team and gain focused as well as broad experiences. Additional opportunities exist to work with external customers and partners who share the same priorities and values as AstraZeneca.

**US Oncology Mission**

*We deliver breakthrough medicines and innovative solutions to transform the treatment and care of patients with serious illnesses for whom every day matters.*
Immuno-Oncology:

- Strategic planning based on the unmet medical needs from the perspectives of patients, providers and payers
- Participation in medical strategy execution through engagement with field medical, medical information, publication strategy, medical education, health policy and outcomes teams
- Represent AstraZeneca at scientific congresses to support the communication of medical information, disease information and competitive insights
- Strategic review the medical literature to identify data and educational gaps to enhance patient care
- Participate in medical slide content development and review
- Participate in scientific communication efforts and dissemination of information internally
- Understand novel clinical and scientific areas of interest for externally sponsor research, and participate in scientific reviews of unsolicited proposals
- Gain an understanding of the laws, regulations, and policies required to help ensure legal and ethical interactions with health care professionals
- Interact with marketing, clinical development, global medical affairs, legal, and regulatory affairs as they relate to US Medical Affairs’ daily
Health Economics & Outcomes Research/Managed Markets:

- Gain an understanding of how HEOR demonstrates the value of AZ products through conduct of studies and communication of value propositions to internal and external stakeholders
- Achieve a diverse experience with the methods and practices of health services, health economics and outcomes research
- Contribute to the generation of HEOR scientific evidence used by healthcare decision makers
- Lead projects used to communicate real-world data with internal and external stakeholders
- Collaborate with cross-functional teams to ensure understanding of HEOR information used to address unmet medical needs
- Learn how HEOR contributes to the wider healthcare quality, performance measures and health policy environment in the US
- Fellows will become active members of project teams and daily operations with in their respective departments, often providing key information to AstraZeneca decision makers
- Gain an understanding of market access principles for biopharmaceuticals including the US healthcare landscape, medical and pharmacy benefit design, and distribution and dispensing models
- Collaborate with field-based MM team members to deliver clinical value presentations to a broad variety of payers and decision-makers

Melissa Pavilack, PharmD
Oncology Business Unit
Associate Director,
Health Economics & Outcomes Research
Fellowship Alum

Among the HEOR fellowships, this program provides a unique experience where the fellow completes rotations throughout different areas of medical affairs to gain a better understanding of how HEOR fits into the Medical Affairs department as a whole. I believe this gives the fellow a great foundation to be a successful member of the team.
The GRAPSQA fellowships are focused two-year fellowships that provide both US and Global experience. The fellows will establish drug development and regulatory/safety foundational knowledge and gain experience working on both development and life-cycle products. In addition, the fellowships will provide training on developing regulatory strategy for approval and maintenance of drugs and biologics.

Global Regulatory Affairs, Patient Safety and Quality Assurance (GRAPSQA) Objectives

Impart working knowledge and skills through project experience including:

- Key aspects of global regulations to apply regulatory requirements to the development, approval and maintenance of drugs and biologics
- Analyze impact of health authority interactions and assess regulatory risks
- Work with matrix team members to identify solutions that meet regulatory requirements as well as commercial objectives
- Interactions between GRAPSQA, other R&D, and non-R&D functions
- Gain CMC, Global Medicines Development, Pharmacovigilance and Global Labeling knowledge
- Gain experience in developing regulatory strategy
- Work with Patient Safety to learn safety regulations, signal detection process and safety aggregate report composition
- Support and develop the reference safety information and risk management plan for designated products
- Provide patient safety input to pivotal study documents (including Investigator brochures, clinical study protocols, and informed consents)
- Perform/support routine signal detection process in partnership with safety physicians and pharmacovigilance scientists
In 1984, at Rutgers, The State University of New Jersey, the Ernest Mario School of Pharmacy and two pharmaceutical companies began a collaborative pilot program to evaluate the potential contributions of clinically-trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program grew significantly and expanded to include 19 companies within the pharmaceutical and biopharmaceutical industries and over 190 fellows annually.

In 2002, Dr. Ernest Mario generously provided an endowment to establish the Institute for Pharmaceutical Industry Fellowships to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- provide leadership and administrative support;
- promote quality, communication, and scholarly activity; and
- arrange specialized fellowship training opportunities within the pharmaceutical and biopharmaceutical industries.

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Distinguished Professor II of the Ernest Mario School of Pharmacy and Dr. Michael Toscani, Research Professor and the Fellowship Director for the Institute for Pharmaceutical Industry Fellowships.

More than 850 post-doctoral fellows have completed the RPIF Program, most of whom are pursuing influential and rewarding careers in the pharmaceutical and biopharmaceutical industries throughout the US and abroad. The RPIF Program has preceptors/mentors from industry who share their knowledge and experiences with the fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industries and the fellow’s functional area.
Professional Development Series

All fellows gather at Rutgers once or twice monthly as a group to participate in the Professional Development Day (PDD) Series, an important component of their training that complements the hands-on experience provided at the partner companies. The PDDs are steered by a committee of fellows and are designed to enhance the fellows' presentation skills, emotional intelligence, promote connectivity and a sense of community among fellows from different companies and disciplines, develop new skill sets under the guidance of external trainers, and provide general knowledge about various aspects of drug development and issues facing the pharmaceutical and biopharmaceutical industries.

The fellows learn from each other through individual and group presentations and debates on topics and issues related to the pharmaceutical and biopharmaceutical industries. This dynamic forum provides an opportunity for open discussion and debate among fellows, Rutgers faculty, and company preceptors. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success; professional writing, presentations, meeting facilitation, negotiating, influencing, networking, and conflict resolution skills; giving and receiving feedback; and business and dining etiquette). Other PDD guest speakers include senior industry executives, patient advocacy groups, and successful RPIF Program alumni who share their insights and experiences. Importantly, PDDs provide an excellent opportunity for fellows to interact with each other and develop lasting personal friendships and a strong professional network of fellows, faculty, alumni, and other industry executives.
The Rutgers Pharmaceutical Industry Fellowship Program FOSTERS the growth and development of future pharmaceutical and biopharmaceutical industry professionals through the following key program features:

- **Family of Leading Companies**–Partners include several of the top 19 global pharmaceutical and biopharmaceutical companies.
- **Outstanding Alumni Track Record**–Over 850 alumni hold prominent positions at many leading companies.
- **Strong Network**—Over 190 fellows each year develop valuable, lasting connections with each other, alumni, preceptors and faculty.
- **The Pathway to Industry**—Since 1984, the Rutgers program has been nationally recognized, trusted, and proven as the pathway to industry for pharmacists.
- **Enhanced Career Path**–Increasingly challenging assignments build depth of experience and enhance the potential for an accelerated career path.
- **Rigorous Academic Component**–Rutgers affiliation provides academic and professional development opportunities.

Rutgers, The State University of New Jersey, with approximately 68,500 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The Ernest Mario School of Pharmacy is the only state school of pharmacy in New Jersey, with approximately 1,300 students in its Doctor of Pharmacy program.

The Rutgers Ernest Mario School of Pharmacy is located on the University’s main science and technology campus in Piscataway, New Jersey. Because of its close proximity to the nation’s leading pharmaceutical and biopharmaceutical companies, the Ernest Mario School of Pharmacy and the RPIF Program are uniquely capable of providing fellows with exposure to the pharmaceutical and biopharmaceutical industries.
Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally-competitive basis. Candidates must have completed a Doctor of Pharmacy degree from an ACPE accredited institution before July 1 of the fellowship term. Participation in the ASHP Midyear Clinical Meeting/PPS is strongly encouraged. Interested individuals are invited to electronically submit a curriculum vitae, three letters of recommendation and a letter of intent and complete a program interest form online by visiting our website at: pharmafellows.rutgers.edu

All application materials must only be submitted electronically via our website, pharmafellows.rutgers.edu (Applicant Portal) as early as November 18th. Applicants are strongly encouraged to submit a CV, Letter of Intent and (1) Letter of Recommendation by December 1st.

Please address your Letter of Intent & Letters of Recommendation to:

Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020

Michael Toscani, PharmD
Research Professor, Fellowship Director
Institute for Pharmaceutical Industry Fellowships
Current Fellows

Corey Fang, PharmD
US Medical Affairs
Second Year Fellow
Medical Operations & Patient Safety
St. John’s University

Daniel Seniuk, PharmD
US Medical Affairs, Oncology Business Unit
Second Year Fellow
Immuno-Oncology Medical Team
Massachusetts College of Pharmacy and Health Sciences University

William McAdoo, PharmD
Global Regulatory Affairs Patient Safety & Quality Assurance
Second Year Fellow
Patient Safety—Oncology
University of North Carolina at Chapel Hill

Daniel Shu, PharmD
Global Regulatory Affairs Patient Safety & Quality Assurance
Second Year Fellow
Regulatory Affairs — Oncology
University of Maryland

Alexis Stinson, PharmD
US Immuno-Oncology Marketing
First Year Fellow
Immuo-Oncology Marketing Team
Thomas Jefferson University
Executive Leadership

US Medical Affairs

Greg Keenan, MD
Vice President & US Head Medical Officer
Gaithersburg, MD

Andrew Coop, MBChB
Vice President, Oncology
Gaithersburg, MD

Jim Blasetto, MD, MPH
Vice President, Evidence Generation
Wilmington, DE

Christine Ney, PharmD
Executive Director, Managed Markets,
Medical Policy & Quality
Wilmington, DE

US Commercial Oncology

Dave Fredrickson
Vice President, US Commercial Oncology
Gaithersburg, MD

Global Regulatory Affairs, Patient Safety and
Quality Assurance (GRAPSQA)

David Wheadon, MD
Senior Vice President, GRAPSQA
Gaithersburg, MD

Hesham Abdullah, MD, MSc, RAC
Vice President, Global Regulatory Affairs,
Oncology & Immuno-Oncology
Gaithersburg, MD

Our Purpose and Values
A Message from our Executive Sponsors
Fellowship Opportunities
US Medical Affairs
Global Regulatory Affairs, Patient Safety and Quality Assurance (GRAPSQA)
Program History
About the Rutgers Component
Key Program Features
Application Process and Eligibility Requirements
Current Fellows
Executive Leadership
Program Leadership
About AstraZeneca
Program Leadership

Marilyn Tsourounis, PharmD, PhD
Regulatory Affairs Director, Oncology
Gaithersburg, MD

Scott Moren, PharmD, MBA
Senior Global Medical Affairs Leader,
Immuno-Oncology
Gaithersburg, MD

Jonathan Jazayeri, PharmD, MS
Regulatory Affairs Director, Oncology
Gaithersburg, MD

Janie Boyer, MS
Brand Manager, Immuno-Oncology
Gaithersburg, MD

Bjorn Bolinder, MBA, MS
Executive Director, Health Economics &
Outcomes Research, Oncology
Gaithersburg, MD

Jung Lee, PharmD
Director, Medical Information,
Cardiometabolic Disease
Wilmington, DE

Makan Sarkeshik, MD
Principal Safety Physician, Oncology
Gaithersburg, MD

Kathryn DeStefano, BPharm, PharmD
Senior Medical Information Manager,
Cardiometabolic Disease
Wilmington, DE

Phananh Pham, PharmD
Senior Medical Information Manager,
Oncology & Immuno-oncology
Gaithersburg, MD
Our Business

- We operate in over 100 countries and our medicines are used by millions of patients worldwide
- We employ around 61,500 people worldwide
- We conduct R&D across 3 continents and we invested over $5.6 billion in R&D during 2015
- We manufacture at 29 sites in 17 countries
- Our sales in 2015 totaled $24.7 billion

A key element of our drive to achieve scientific leadership is our focus on innovative science in three therapy areas: Respiratory, Inflammation and Autoimmunity (RIA); Cardiovascular and Metabolic diseases (CVMD); and Oncology. We apply our distinctive capabilities to small molecules, biologics, immunotherapies, protein engineering technologies and delivery devices across these therapy areas.

Cardiovascular and metabolic diseases

Our strategy and focus is on bringing life-changing medicines to patients to reduce morbidity, mortality and organ damage by addressing multiple risk factors across cardiovascular (CV) disease, including thrombosis (blood clotting), atherosclerosis (hardening of the arteries), dyslipidemia (abnormal levels of blood lipids), and hypertension, diabetes and chronic kidney disease (CKD). Despite improvements in the diagnosis and treatment of CVMD, unmet medical need remains high. The prevalence of these diseases and associated complications continues to increase worldwide.

An estimated 17.5 million people die annually from CV disease, representing 31% of all global deaths. More than three-quarters of these deaths occur in low- to middle-income countries.* It is estimated that 415 million people worldwide have diabetes; WHO projects that diabetes will be the seventh leading cause of death in 2030.**


Oncology

Cancer is a leading cause of death worldwide and accounted for 8.2 million deaths in 2012*. Even as research and development continues to break boundaries in how we understand and fight cancer, there are still more than eight million lives lost every year to the disease. At AstraZeneca, we are committed to advancing the science of oncology to deliver life-changing medicines to people most in need. Our combination-focused pipeline exploits the power of four scientific platforms, and we are driven by an ambition to help eliminate cancer as a cause of death through scientific discovery and collaborations.


Respiratory, Inflammation and Autoimmune diseases

For 40 years, AstraZeneca has pushed the boundaries of science and helped millions of patients with respiratory disease. Now in RIA, we are advancing a pipeline of inhaled and biologic treatments, drug combinations and devices, and other therapies that aim to transform disease management.

The global prevalence of COPD is estimated to be 329 million people and WHO predicts that COPD will become the third leading cause of death worldwide by 2030*. It is estimated that approximately 300 million people worldwide suffer from asthma**.

*Source: Vos et al 2012 WHO.

To learn more about our products and pipeline, please visit www.astrazeneca.com
AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK – two companies with similar science-based cultures and a shared vision of the pharmaceutical industry.

CORPORATE RESPONSIBILITY
We are deeply committed to making a meaningful difference in the lives of people and the communities in which they live.

Advancing Patient Health
We support programs aligned to our core therapeutic areas that increase disease awareness, improve health literacy, and empower patients to manage their health.

Increasing Access to Care
In the U.S. and globally, we support improved healthcare delivery and access to medication for underserved patients and communities with the greatest unmet need.

Driving Health & Science Innovation
We support STEM education and medical training for students and practitioners to develop the next-generation of scientists and problem solvers.

Supporting Communities
We assist communities to ensure they are equipped with the resources and programs to thrive year-round.

GAITHERSBURG
1 MedImmune Way
Gaithersburg, MD 20878
301-398-0000

WILMINGTON
1800 Concord Pike
P.O. Box 15437
Wilmington, DE 19850
302-886-3000

http://www.astrazenecacareers.com